Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 T-DM1 for HER2 exon 20 insertion–positive NSCLC
jRCT2080224551Phase 2Completed
- Sponsor
- Kyushu University Hospital
- Start
- Feb 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab emtansine in non-small cell lung cancer (NSCLC), sponsored by Kyushu University Hospital. Started Feb 2019; status: completed.
02
Drugs
trastuzumab emtansine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080224551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224551.